EDESA BIOTECH INC (EDSA) Stock Price, Quote, News and Overview
NASDAQ:EDSA - Nasdaq - CA27966L3065 - Common Stock - Currency: USD
EDSA Quote, Performance and Key Statistics
2.3841
+0 (+0.17%)
The current stock price of EDSA is 2.3841 USD. In the past month the price increased by 2.76%. In the past year, price decreased by -48.54%.
EDSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About EDSA
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. The company is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. The company has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The company is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.
Company Info
EDESA BIOTECH INC
100 Spy Crt
Markham ONTARIO L3R 5H6 CA
CEO: Pardeep Nijhawan
Employees: 16
Phone: 19054751234
EDESA BIOTECH INC / EDSA FAQ
What is the stock price of EDESA BIOTECH INC today?
The current stock price of EDSA is 2.3841 USD. The price increased by 0.17% in the last trading session.
What is the ticker symbol for EDESA BIOTECH INC stock?
The exchange symbol of EDESA BIOTECH INC is EDSA and it is listed on the Nasdaq exchange.
On which exchange is EDSA stock listed?
EDSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EDESA BIOTECH INC stock?
7 analysts have analysed EDSA and the average price target is 19.38 USD. This implies a price increase of 712.89% is expected in the next year compared to the current price of 2.3841. Check the EDESA BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EDESA BIOTECH INC worth?
EDESA BIOTECH INC (EDSA) has a market capitalization of 16.74M USD. This makes EDSA a Nano Cap stock.
How many employees does EDESA BIOTECH INC have?
EDESA BIOTECH INC (EDSA) currently has 16 employees.
What are the support and resistance levels for EDESA BIOTECH INC (EDSA) stock?
EDESA BIOTECH INC (EDSA) has a support level at 2.38 and a resistance level at 2.4. Check the full technical report for a detailed analysis of EDSA support and resistance levels.
Should I buy EDESA BIOTECH INC (EDSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EDSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EDSA, evaluating the profitability, health, valuation and growth aspects
- EDESA BIOTECH INC (EDSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EDESA BIOTECH INC (EDSA) Sales and EPS estimates to see what analysts future expectations are.
- EDESA BIOTECH INC (EDSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EDESA BIOTECH INC (EDSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- EDESA BIOTECH INC (EDSA) Stock Chart to make your own analysis
- EDESA BIOTECH INC (EDSA) Latest news and press-releases to stay up to date.
Does EDESA BIOTECH INC (EDSA) stock pay dividends?
EDSA does not pay a dividend.
When does EDESA BIOTECH INC (EDSA) report earnings?
EDESA BIOTECH INC (EDSA) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of EDESA BIOTECH INC (EDSA)?
EDESA BIOTECH INC (EDSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).
What is the Short Interest ratio of EDESA BIOTECH INC (EDSA) stock?
The outstanding short interest for EDESA BIOTECH INC (EDSA) is 0.96% of its float. Check the ownership tab for more information on the EDSA short interest.
EDSA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EDSA. When comparing the yearly performance of all stocks, EDSA is a bad performer in the overall market: 71.15% of all stocks are doing better.
EDSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EDSA. EDSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EDSA Financial Highlights
Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 30.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.71% | ||
| ROE | -269.83% | ||
| Debt/Equity | 0 |
EDSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EDSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.